GSK (GSK): Specialty Medicines Drive a Re-Rating

Thesis

GSK(GSK) fits a balanced, moderate-risk portfolio as a large-cap biopharma with three traits that matter in this market: durable cash generation, a portfolio shift toward faster-growing specialty medicines, and a valuation that still looks reasonable against its growth profile. In 2025, revenue rose 6.2% to $31.95B, net income climbed to $5.59B from $2.58B in 2024, and free cash flow reached $8.46B, equal to a 7.78% FCF yield. That is not a story stock. It is a cash machine that is trying to become a better growth business.

The core bull case rests on mix shift. Management said 2025 sales rose 7% to more than £32B, driven by Specialty Medicines up 17%, while Q1 2026 kept that pattern going with Specialty Medicines at £3.2B, up 14%, versus General Medicines down 6% to £2.3B. That matters because specialty products usually carry better pricing power, stronger intellectual property, and better margin structure. GSK’s gross margin reached 72.5% in 2025, up from 71.2% in 2024, while operating margin rebounded to 21.9% from 12.8%.

The main risk is equally clear. GSK still needs its pipeline and launch portfolio to outrun pricing pressure, generic competition in legacy products, and the long-term HIV loss of exclusivity issue management explicitly discusses. The company has momentum, but it also has work to do. For a medium-term investor, that combination supports a Buy rating, with our fair value estimate of $52 anchored by a reasonable earnings multiple, strong cash returns, and a pipeline that is broad enough to support steady rerating if execution holds.

Company Overview

GSK plc is a London-based global biopharma company whose ADR trades on the NYSE under GSK. The company employs 66,841 people and operates across vaccines, specialty medicines, and general medicines. Its current shape is far more focused than the old GlaxoSmithKline model. Management now centers the business on higher-value categories including HIV, respiratory and immunology, oncology, and vaccines.

That focus is visible in the numbers. GSK generated 2025 revenue of $31.95B and carries a market cap of about $108.7B. Trailing P/E stands at 14.5x, while forward P/E is 21.0x. EBITDA was $11.34B, and net margin was 17.5%. Those figures place GSK in the camp of mature pharma companies with meaningful profitability, but the operating story is improving because the faster-growing parts of the portfolio are gaining weight.

Management’s strategic message is straightforward. In the FY2025 results call, Luke Miels said, “2025 was a strong year for GSK. For 2026, we're guiding for another year of top line growth and operating leverage.” The company reaffirmed 2026 guidance for turnover growth of 3% to 5%, core operating profit growth of 7% to 9%, and core EPS growth of 7% to 9%. It also reiterated a 2031 sales outlook of more than £40B.

For investors, the appeal is not that GSK is the fastest-growing drug company in the market. It is that the company already has scale, dividends, buybacks, and global commercial infrastructure, while still showing genuine growth in several franchises. That is a useful combination when the market rewards both resilience and execution.

Business Segment Deep Dive

GSK reports through Commercial Operations and Total R&D, but the commercial engine is best understood through three product groups: Specialty Medicines, Vaccines, and General Medicines. The direction of travel is favorable. In 2025, management reported Specialty Medicines up 17%, Vaccines up 2%, and General Medicines slightly down. In Q1 2026, the split was £3.2B for Specialty Medicines, £2.1B for Vaccines, and £2.3B for General Medicines.

Specialty Medicines is the growth engine. Within that bucket, respiratory, immunology, oncology, and HIV all posted double-digit growth in 2025. Q3 2025 gives a useful snapshot: HIV generated £1.944B, up 12%; RI&I produced £954M; and Oncology reached £511M. Management expects Specialty Medicines sales to grow low double digit in 2026, which is the strongest growth outlook inside the portfolio.

Vaccines remains a major profit and scale pillar rather than a pure growth rocket. In 2025, vaccine sales were £9.2B, up 2%, with Shingrix at £3.6B, up 8%, meningitis sales up 12%, and Arexvy up 2%. Q1 2026 vaccines revenue rose 4% to £2.1B. This segment gives GSK something many peers would like to have: a large, global vaccine platform with meaningful manufacturing and commercial barriers.

General Medicines is the ballast and the drag at the same time. It still contributes large revenue, including Trelegy, but management guides the segment to low single-digit decline to stable in 2026 because of pricing pressure and generic competition. In plain English, this is the old engine still running, but the company wants the new engine to do more of the work.

The segment mix is important for valuation. If Specialty Medicines keeps compounding faster than the rest of the business, GSK deserves to trade less like a slow primary-care pharma name and more like a hybrid of cash-rich pharma and specialty growth. That rerating case is the heart of the investment story.

Flagship Product Analysis

Shingrix is still GSK’s flagship commercial asset because it combines scale, brand durability, and international runway. In 2025, Shingrix sales reached £3.6B, up 8%. Growth came from Europe and international markets, with Japan benefiting from expanded public funding, while the U.S. was softer. That pattern matters because it shows the franchise is no longer just a U.S. story.

The product is strategically important beyond its own revenue. Shingrix helps anchor GSK’s vaccine identity, supports manufacturing scale, and gives the company a large installed commercial base in adult immunization. In a market where vaccine demand can swing by season and region, a global franchise with established reimbursement and physician familiarity is valuable.

That said, Shingrix is not the only product investors should watch. Nucala delivered $2B in 2025, up 15%, marking its 10th consecutive year of double-digit growth. Jemperli sales rose 89% in 2025. Cabenuva grew 42%, and Apretude grew 62%. Trelegy remained the top-selling brand for asthma and COPD globally. GSK has several products that can claim flagship status inside their own categories, which reduces single-product dependence.

For a medium-term investor, the key takeaway is that GSK’s flagship set is broadening. Shingrix remains the commercial anchor, but the next phase of value creation depends more on the combined lift from Nucala, Benlysta, Jemperli, Cabenuva, Apretude, Ojjaara, and newer launches like Exdensur and Blenrep. That is healthier than relying on one blockbuster to carry the whole case.

Innovation & Competitive Advantage

GSK’s moat comes from three things: scientific depth in selected disease areas, global vaccine and biologics manufacturing scale, and a growing long-acting treatment platform in HIV and respiratory disease. In 2025, management cited 5 FDA approvals and 7 new pivotal trial starts. Industry context adds more weight: GSK reported 58 assets in phase III or registration and 17 pivotal trial starts in 2025.

The HIV platform is one of the clearest competitive advantages. Deborah Waterhouse said 2025 HIV sales growth was 11%, with more than 75% of growth coming from long-acting injectables, which now represent around one-third of U.S. sales. Cabenuva grew 42%, and Apretude grew 62%. GSK also said it has the only commercially established long-acting HIV treatment regimen backed by more than 4 years of real-world data. In pharma, real-world evidence plus commercial lead time can be a serious moat.

Respiratory and immunology is another strength. Exdensur is approved in the U.S., U.K., and Japan as the first and only 6-monthly biologic for severe eosinophilic asthma, according to management. Nina Mojas said it demonstrated a 72% reduction in exacerbations leading to hospitalizations. Nucala’s COPD launch also created what management called a halo effect across asthma and nasal polyps. That is how a franchise becomes sticky: one product helps the next product sell.

Oncology is the higher-risk, higher-upside piece. Jemperli grew 89% in 2025, Ojjaara rose 60%, and GSK is pushing BLENREP, B7-H3, B7-H4, and Velzatinib through late-stage development. Tony Wood said the company plans multiple pivotal starts for ADC programs. If even part of that portfolio lands well, oncology can become a much larger contributor by the end of the decade.

Business development also supports the moat. GSK announced the acquisition of Rapp Therapeutics for ozureprubart, a Phase II long-acting anti-IgE monoclonal for food allergy, and management highlighted completed acquisitions of ozureprubart and HS235 in Q1 2026 commentary. The company is not buying random science projects. It is adding assets that fit existing commercial and scientific lanes.

Operations & Supply Chain

Operations are improving in ways that matter financially. Julie Brown said 2025 core operating profit grew 11% while SG&A rose only 3%, as launch investment was balanced with productivity improvements. She also said operating margin increased 110 basis points in 2025, bringing total accretion at constant exchange rates to 470 basis points over the last 4 years.

Gross margin also moved the right way. Annual financial statements show gross margin improved from 71.2% in 2024 to 72.5% in 2025. Management linked that to supply chain efficiencies and the portfolio transition toward specialty products. In pharma, mix shift is often more powerful than cost cutting. Selling more high-value biologics and specialty medicines tends to do the heavy lifting.

Cash conversion remains solid even after legal and investment demands. Management said cash generated from operations was £8.9B in 2025, or more than £10B excluding Zantac payments, while free cash flow was £4B, or more than £5B excluding Zantac. The financial data set shows operating cash flow of $7.14B and free cash flow of $8.46B for fiscal 2025, with a 7.78% FCF yield. The exact presentation differs by reporting basis, but the broad message is the same: this business throws off meaningful cash.

Supply chain scale is another underappreciated asset. GSK said it delivered 1.7 billion packs of medicines and 400 million vaccine doses in the prior year, and it announced a $30B U.S. investment over five years in R&D and manufacturing. That kind of footprint is expensive to build and hard to replicate. In a regulated industry, scale is not just size. It is a barrier.

Market Analysis

GSK operates in a pharmaceutical market that is growing at a mid-single-digit pace overall, but its chosen submarkets can grow faster. Industry data cited here puts the global pharmaceutical market at a 4.05% CAGR, while the U.S. market is projected to grow 5.72% annually through 2030. That is the tide. GSK’s strategy is to fish in the faster parts of the pond: specialty medicines, vaccines, oncology, long-acting HIV, and advanced respiratory therapies.

Management’s own numbers support that positioning. In 2025, Specialty Medicines reached £13.5B, up 17% CER, while Vaccines delivered £9.2B, up 2% CER. General Medicines totaled £10.0B and declined 1% CER. The company expects Specialty Medicines to contribute more than 50% of sales by 2031. That is a meaningful reshaping of the revenue base.

The addressable opportunity is large enough to matter. GSK reiterated a 2031 sales ambition of more than £40B and said its late-stage pipeline has non-risk-adjusted peak-year sales potential of more than £20B. That does not guarantee delivery, but it does show the company is operating in markets with enough room to absorb multiple launches.

Convenience is becoming a competitive weapon across pharma, and GSK is aligned with that trend. Long-acting HIV regimens, a 6-monthly asthma biologic, and adherence-friendly specialty products all fit a market that increasingly rewards outcomes plus ease of use. In other words, better medicine still wins, but better medicine that asks less of the patient wins faster.

Customer Profile

GSK’s end customers are broad, but the buying chain is specialized. The company sells into hospitals, physicians, health systems, wholesalers, pharmacies, public immunization programs, and national health systems. In vaccines, government and public-health channels matter heavily. In specialty medicines, specialist prescribers, reimbursement bodies, and integrated delivery networks carry more weight.

The patient profile is concentrated in chronic, high-burden diseases where adherence and long-term outcomes matter. That is especially clear in HIV, lupus, severe asthma, COPD, shingles prevention, meningitis prevention, and oncology. These are not one-off consumer purchases. They are categories where clinical differentiation, safety history, and access support durable demand.

Management repeatedly highlighted bio-naive and switch populations as commercial targets. Benlysta now starts 82% of U.S. bio-naive patients, according to management. Exdensur market research showed 97% of patients would prefer or like to switch to a biologic with 6-monthly dosing. Cabenuva’s growth was fueled by switches from competitor products. That tells you GSK’s customer strategy is not just about finding untreated patients. It is also about winning conversions.

This matters because switching behavior can create operating leverage. Once a physician network is trained, reimbursement pathways are established, and patient support systems are in place, each additional converted patient can be more profitable than the first. That is one reason specialty medicine growth often carries better margin quality than legacy primary-care volume.

Competitive Landscape

GSK competes with different groups depending on the franchise. In vaccines, key rivals include Pfizer(PFE), Merck(MRK), Sanofi(SNY), AstraZeneca(AZN), Moderna(MRNA), CSL(CSL), and Bavarian Nordic(BVNKF). In specialty medicines, the field broadens to AstraZeneca(AZN), Novartis(NVS), Roche(RHHBY), Merck(MRK), Pfizer(PFE), Bristol Myers Squibb(BMY), AbbVie(ABBV), Eli Lilly(LLY), Johnson & Johnson(JNJ), and Sanofi(SNY).

GSK’s competitive edge is strongest where it has either a differentiated product or a commercial lead. In HIV, management says it has the only commercially established long-acting treatment regimen. In vaccines, Shingrix and the broader franchise give it scale that few peers can match. In respiratory, Nucala and Exdensur create a layered position across asthma and COPD. In oncology, the company is still building, but Jemperli and Ojjaara show that the effort is producing real commercial traction.

The weak spot is that GSK does not dominate every category it enters, and some of its legacy businesses face the classic pharma problems of pricing pressure and generic erosion. Management explicitly noted ZEJULA sales decreased because of FDA labeling restrictions, and General Medicines faces pricing pressure and generic competition. This is why the mix shift is so important. It is not cosmetic. It is the difference between multiple expansion and multiple stagnation.

Peer comparison data by valuation multiple is limited here because the peer screen failed, so the competitive read has to lean on business facts rather than a neat spreadsheet. Even so, the strategic picture is clear: GSK is no longer trying to be everything. It is trying to be very good in a few places that can support durable growth.

Macro & Geopolitical Landscape

Healthcare is usually less cyclical than most sectors, and GSK’s beta of 0.354 reflects that defensive profile. For a moderate-risk investor, that matters. The stock should not move like a semiconductor name every time bond yields twitch. But defensive does not mean insulated. Pharma still faces currency swings, pricing reform, regulatory shifts, and supply chain politics.

Currency is a real variable for GSK. Julie Brown said that if exchange rates held at January 28 closing levels, 2026 would face a minus 3% impact on sales and minus 6% on operating profit. For a U.K.-based global company with ADR trading in the U.S., foreign exchange can blur otherwise solid operating progress.

Policy pressure is also real. Management said the company navigated the impact of the Medicare redesign from the Inflation Reduction Act near the upper end of its $400M to $500M range in the U.S. That is a concrete reminder that even strong products can face reimbursement headwinds. The industry context also points to continued pressure on drug pricing and broader regulatory efforts to accelerate biosimilar competition.

On the positive side, manufacturing resilience and domestic investment are becoming strategic advantages. FDA and broader policy trends favor onshoring and supply reliability, and GSK’s announced $30B U.S. investment in R&D and manufacturing should strengthen its standing in that environment. In geopolitics, scale and local presence are often the closest thing to an insurance policy.

Balance Sheet Health

Income Statement Strength

Estimates Outlook

Valuation Assessment

Target Prices & Recommendation

Closing

GSK is not a perfect story, and that is part of why the opportunity still exists. The company has a real legacy drag, real policy exposure, and real pipeline execution risk. But it also has real growth in specialty medicines, real vaccine scale, real cash flow, and a management team that is hitting enough marks to keep the medium-term case intact.

The best way to frame GSK today is as a company in the middle of a quality upgrade. Revenue growth is not explosive, but the mix is improving. Margins are not peak-level across every quarter, but the trend is better. The pipeline is not fully de-risked, but it is broad and active. That combination usually does not stay cheap forever if execution keeps landing.

For investors with a medium-term horizon, GSK offers a sensible path to total return through earnings growth, dividends, buybacks, and some valuation support. That is why the stock earns a Buy rating, with our fair value estimate of $52 as the central anchor.